Tenderwize
Wróć do wyszukiwania

Open-house rebate agreements for Rivaroxaban film-coated tablets excluding 2.5 mg

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Jul 03, 2027 · 309 days left·Open·Supplies·Framework
Zarejestruj się, aby zapisaćOpen documents
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Rivaroxaban Filmtabletten, ausgenommen in der Wirkstärke 2,5 mg, ATC B01AF01

62/100

Ocena szansy

Needs reviewMedium complexity
SuppliesFrameworkOpen
Skąd ta ocena?

Szansa

62 / 100

Złożoność

58 / 100

Czynniki ryzyka

The notice states the arrangement is an open-house model and not a procurement procedure in the usual sense; legal reme...

Contract documents submitted through the wrong portal area are expressly forbidden; submission must go via the DTVP com...

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Aug 2027
  • Non-exclusive supply/rebate agreement for Rivaroxaban film-coated tablets, excluding 2.5 mg strength.
  • Open-house model with identical, non-individually negotiable contract terms.
Pokaż pełne podsumowanie

This is an open-house pharmaceutical supply arrangement by AOK Bayern for Rivaroxaban film-coated tablets excluding the 2.5 mg strength (CPV 33600000). It is explicitly described as non-exclusive and non-negotiated, with contracts offered to all interested pharmaceutical companies that meet the stated suitability requirement. The notice includes electronic and paper submission options via DTVP or by post, with strict monthly cut-off rules for contract start dates. No contract value is stated.

Ryzyka

The notice states the arrangement is an open-house model and not a procurement procedure in the usual sense; legal reme...

Contract documents submitted through the wrong portal area are expressly forbidden; submission must go via the DTVP com...

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Eligibility

  • Only pharmaceutical companies are eligible as potential contract partners.

Administrative

  • Signed declaration of reliability (Eigenerklärung zur Zuverlässigkeit) must be submitted.
  • Signed contract and completed annex 'Festlegung der vertragsgegenständlichen Arzneimittel' must be submitted.

Zamawiający

Lokalizacja

München, DEU

Profil zamawiającego

Otwórz profil

Identyfikator

DE811695320

Działalność

Health

Części (1)

LOT-0001

Open-house rebate agreements for Rivaroxaban film-coated tablets excluding 2.5 mg

Open-house framework-style supply arrangement for Rivaroxaban film-coated tablets, excluding the 2.5 mg strength, for AOK Bayern. The lot description states that contract documents must be submitted via the communication area in the DTVP portal, not via the offer area. The lot is explicitly open to all interested pharmaceutical companies meeting the suitability requirement; information in the notice indicates a maximum of 999 operators may join.

SuppliesFrameworkEU fundedElectronic submission

Lokalizacja

DE212, Germany

Czas trwania

Aug 2025 - Aug 2027

Kategoria

Pharmaceutical products

Termin

Deadline Jul 03, 2027

Szczegóły zamówienia

Data publikacji
13 Jul 2025
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
457937-2025

Dokumenty (2)

Dokument zamówienia 1Portal składania ofert 1

Podobne przetargi

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30